Pillar Pacific Capital Management LLC held its stake in Amedisys Inc. (NASDAQ:AMED) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,700 shares of the company’s stock at the end of the third quarter. Pillar Pacific Capital Management LLC’s holdings in Amedisys were worth $412,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of AMED. KBC Group NV raised its position in shares of Amedisys by 28.2% in the third quarter. KBC Group NV now owns 87,004 shares of the company’s stock valued at $4,127,000 after buying an additional 19,135 shares during the last quarter. Victory Capital Management Inc. purchased a new position in shares of Amedisys during the third quarter valued at about $38,456,000. Aperio Group LLC raised its position in shares of Amedisys by 3.5% in the third quarter. Aperio Group LLC now owns 11,971 shares of the company’s stock valued at $568,000 after buying an additional 409 shares during the last quarter. Gilder Gagnon Howe & Co. LLC purchased a new position in shares of Amedisys during the third quarter valued at about $42,527,000. Finally, Quantbot Technologies LP raised its position in shares of Amedisys by 717.9% in the third quarter. Quantbot Technologies LP now owns 2,699 shares of the company’s stock valued at $128,000 after buying an additional 2,369 shares during the last quarter. Institutional investors own 97.02% of the company’s stock.
Shares of Amedisys Inc. (NASDAQ:AMED) traded up 1.44% during midday trading on Friday, reaching $41.66. 135,976 shares of the company were exchanged. The company’s 50-day moving average price is $42.94 and its 200 day moving average price is $48.33. Amedisys Inc. has a 52-week low of $31.16 and a 52-week high of $55.16. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of 33.98 and a beta of 1.45.
Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Thursday, November 3rd. The company reported $0.36 EPS for the quarter, missing analysts’ consensus estimates of $0.44 by $0.08. Amedisys had a return on equity of 11.94% and a net margin of 2.93%. The firm earned $361.60 million during the quarter, compared to analyst estimates of $361.08 million. During the same quarter in the prior year, the firm earned $0.34 EPS. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. On average, equities analysts predict that Amedisys Inc. will post $1.49 earnings per share for the current year.
Several equities analysts have issued reports on AMED shares. Mizuho lowered Amedisys from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $57.00 to $55.00 in a report on Wednesday, August 3rd. Zacks Investment Research raised Amedisys from a “sell” rating to a “hold” rating in a report on Thursday, August 4th. Jefferies Group reissued a “buy” rating on shares of Amedisys in a report on Tuesday, September 6th. Finally, Wells Fargo & Co. reissued a “buy” rating on shares of Amedisys in a report on Sunday, September 11th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company’s stock. Amedisys presently has a consensus rating of “Hold” and an average target price of $50.29.
Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.